VIDEO: Lenvatinib ups PFS in thyroid cancer

CHICAGO – Lenvatinib significantly prolonged progression-free survival and produced high response rates compared with placebo in patients with relapsed iodine-refractory differentiated thyroid cancer. We catch up with study coauthor Dr. Lori C. Wirth, medical director of the Center for Head and Neck Cancers at Massachusetts General Hospital, Boston, to discuss the promising results at the annual meeting of the American Society of Clinical Oncology.

The study was funded by Eisai. Dr. Wirth reported no financial disclosures.

CHICAGO – Lenvatinib significantly prolonged progression-free survival and produced high response rates compared with placebo in patients with relapsed iodine-refractory differentiated thyroid cancer. We catch up with study coauthor Dr. Lori C. Wirth, medical director of the Center for Head and Neck Cancers at Massachusetts General Hospital, Boston, to discuss the promising results at the annual meeting of the American Society of Clinical Oncology.

The study was funded by Eisai. Dr. Wirth reported no financial disclosures.

CHICAGO – Lenvatinib significantly prolonged progression-free survival and produced high response rates compared with placebo in patients with relapsed iodine-refractory differentiated thyroid cancer. We catch up with study coauthor Dr. Lori C. Wirth, medical director of the Center for Head and Neck Cancers at Massachusetts General Hospital, Boston, to discuss the promising results at the annual meeting of the American Society of Clinical Oncology.

The study was funded by Eisai. Dr. Wirth reported no financial disclosures.